ClinicalTrials.gg
CompletedNCT01519778Updated Aug 29, 2018Results posted

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

A Phase 2 interventional study of TR701 FA in Major Cutaneous Abscess, Cellulitis and Erysipelas, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-29.

Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Cellulitis with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Cellulitis · United States.

Enrollment
30th of 65
200 · median 153
Started
2012
with 8 others
Phase 2
14 of 75
none open now
Registered
40th of 75
by date

Among the 75 studies in Cellulitis with a site in United States, this one is the 30th largest by enrollment of the 65 interventional ones that give a count, is one of 9 that started in 2012, is one of 14 in phase 2, and was the 40th registered.

Cellulitis

160 studies on the registry are indexed under Cellulitis; 14 are open to participants now.

Browse Cellulitis studies →

Open to participants now

1 of the 75 studies in Cellulitis with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Cellulitis studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cellulitis with a site in United States, or all of them as a file.
02

Study summary

Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.

Read the detailed description

This is an open-label, multicenter study of oral TR-701 FA 200 mg once daily for 6 days for the treatment of major cutaneous abscess or cellulitis/erysipelas in patients 18 years of age or older. This study is designed to further characterize the safety profile and gather additional lesion measurement data of TR-701 FA in patients with major cutaneous abscess or cellulitis/erysipelas.

03

Conditions studied

  • Major Cutaneous Abscess
  • Cellulitis
  • Erysipelas

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 18 years of age
  • Suspected or documented gram-positive infection from baseline Gram stain or culture.
  • Cellulitis/erysipelas or major cutaneous abscesses at Screening

Exclusion criteria

Exclusion Criteria:

  • Postsurgical or open wound infections
  • Severe sepsis or septic shock
  • Uncomplicated skin and skin structure infections such as furuncles, minor abscesses (\< 75 cm2 or area of suppuration not surrounded by cellulitis/erythema), and impetiginous lesions
  • Infections associated with, or in close proximity to, a prosthetic device
  • Known bacteremia or osteomyelitis at time of screening
05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    TR-701 FA

    Drug: TR701 FA

Interventions

  • 1 tablet 200 mg once daily

    Also known as: Tedizolid

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Safety will be assessed through summaries of the incidence of AEs and SAEs as well as through summaries of vital signs, physical examinations, ECG findings, and laboratory assessments (hematology, serum chemistry, and urinalysis).

    Time frame: 24-31 days

07

Results

Posted Mar 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneTR-701 FA
Started200
Completed186
Not completed14
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up10
Withdrew: Physician decision1

Outcome measures

PrimaryIncidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Safety will be assessed through summaries of the incidence of AEs and SAEs as well as through summaries of vital signs, physical examinations, ECG findings, and laboratory assessments (hematology, serum chemistry, and urinalysis).

Time frame:
24-31 days
Reported as:
Number · participants
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsTR-701 FA
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)91

Adverse events

Collected over From the Informed Consent Form signature through the late follow-up visit, up to 32 days.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TR-701 FA—2/200 (1%)58/200 (29%)
Most frequent serious events
Most frequent serious events
EventTR-701 FA
hemoptysisRespiratory, thoracic and mediastinal disorders1/200
thrombophlebitis septicInfections and infestations1/200
Most frequent other events
Most frequent other events
EventTR-701 FA
NauseaGastrointestinal disorders22/200
diarrheaGastrointestinal disorders13/200
cellulitisInfections and infestations10/200
abscessInfections and infestations9/200
vomitingGastrointestinal disorders9/200
dizzinessNervous system disorders7/200
headacheNervous system disorders7/200
chillsGeneral disorders4/200
constipationGastrointestinal disorders4/200
somnolenceNervous system disorders4/200

Baseline characteristics

Age, Continuous
Age, Continuous(years)TR-701 FA
Mean39.5 ± 13.04
Sex: Female, Male
Sex: Female, Male(Participants)TR-701 FA
Female71
Male129
08

Study locations

10 sites
  • Trius Investigator Site #118
    Anaheim, California 92804, United States
  • Trius Investigator Site #129
    Buena Park, California 90620, United States
  • Trius Investigator Site 103
    Chula Vista, California 91911, United States
  • Trius Investigator Site 105
    La Mesa, California 91942, United States
  • Trius Investigator Site #106
    Long Beach, California 90813, United States
  • Trius Investigator Site 104
    Oceanside, California 92056, United States
  • Trius Investigator Site 101
    Columbus, Georgia 31904, United States
  • Trius Investigator Site 102
    Savannah, Georgia 31406, United States
  • Trius Investigator Site 128
    Las Vegas, Nevada 89109, United States
  • Trius Investigator Site 115
    Somers Point, New Jersey 08244, United States
09

References and documents

Publications

  • Powers JH 3rd, Das AF, De Anda C, Prokocimer P. Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain. Contemp Clin Trials. 2016 Sep;50:265-72. doi: 10.1016/j.cct.2016.08.010. Epub 2016 Aug 13. PubMed 27530088 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2012 to primary completion in Aug 2012, 6 months.

Results were first posted in Mar 2015, 2 years 6 months after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2012
First posted
Jan 27, 2012
StartActual
Feb 15, 2012
Primary completionActual
Aug 27, 2012
CompletionActual
Aug 27, 2012
Results delay requested
Apr 2, 2014
Results first posted
Mar 12, 2015
Last update
Aug 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01519778
Collaborators
Bayer
Responsible party
Sponsor
First posted
Jan 27, 2012
Start date
Feb 15, 2012
Primary completion
Aug 27, 2012
Completion
Aug 27, 2012
Results posted
Mar 12, 2015
Last update
Aug 29, 2018

Study contacts

Philippe Prokocimer, MD
study chair · Trius Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion